Literature DB >> 11161376

Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients.

L Laghi1, P Bianchi, O Orbetegli, L Gennari, M Roncalli, A Malesci.   

Abstract

A truncating mutation (C to T transition) at codon 531 of the human protooncogene c-src, possibly accounting for the activation of c-src tyrosine kinase, has been recently identified in a subset of advanced colorectal cancer from North-American patients. However, two subsequent studies have failed to confirm the occurrence of SRC 531 mutation in colorectal cancers from North-European and Asiatic patients, raising the hypothesis that the genetic activation of src in colon cancer might be restricted to patients belonging to specific ethnic groups. We investigated a large series of colorectal cancers from Italian patients (155 cases) with a high prevalence of liver metastasis (43%). Using a PCR-RFLP assay, the occurrence of a SRC 531 mutation was ruled out in all the investigated specimens of primary tumours and/or metastases. Our results demonstrate that SRC Gln531AMB plays no role in the development or in the progression of colorectal cancer among Italian patients. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161376      PMCID: PMC2363715          DOI: 10.1054/bjoc.2000.1560

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

2.  c-src activating mutation analysis in Chinese patients with colorectal cancer.

Authors:  Ye-Xiong Tan; Han-Tao Wang; Peng Zhang; Zhong-Hua Yan; Guan-Long Dai; Meng-Chao Wu; Hong-Yang Wang
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

3.  Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.

Authors:  Priya Koppikar; Seung-Ho Choi; Ann Marie Egloff; Quan Cai; Shinsuke Suzuki; Maria Freilino; Hiroshi Nozawa; Sufi M Thomas; William E Gooding; Jill M Siegfried; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

4.  SNX10 (sorting nexin 10) inhibits colorectal cancer initiation and progression by controlling autophagic degradation of SRC.

Authors:  Sulin Zhang; Zhiwen Yang; Weilian Bao; Lixin Liu; Yan You; Xu Wang; Liming Shao; Wei Fu; Xinhui Kou; Weixing Shen; Congmin Yuan; Bin Hu; Wenzhen Dang; Kutty Selva Nandakumar; Hualiang Jiang; Mingyue Zheng; Xiaoyan Shen
Journal:  Autophagy       Date:  2019-07-04       Impact factor: 16.016

5.  Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.

Authors:  Nagathihalli S Nagaraj; J Joshua Smith; Frank Revetta; M Kay Washington; Nipun B Merchant
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

Review 6.  [SRC kinases in tumor therapy].

Authors:  Wolfram Dempke; Roland Zippel
Journal:  Med Klin (Munich)       Date:  2010-10-28

7.  Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer.

Authors:  Elizabeth M Poole; Karen Curtin; Li Hsu; Richard J Kulmacz; David J Duggan; Karen W Makar; Liren Xiao; Christopher S Carlson; Martha L Slattery; Bette J Caan; John D Potter; Cornelia M Ulrich
Journal:  Int J Mol Epidemiol Genet       Date:  2011-12-03

Review 8.  Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Authors:  Manmeet S Ahluwalia; John de Groot; Wei Michael Liu; Candece L Gladson
Journal:  Cancer Lett       Date:  2010-12-08       Impact factor: 8.679

Review 9.  The role of Src in solid tumors.

Authors:  Deric L Wheeler; Mari Iida; Emily F Dunn
Journal:  Oncologist       Date:  2009-07-06

10.  Evolving role of cetuximab in the treatment of colorectal cancer.

Authors:  Gunter Schuch; Sebastian Kobold; Carsten Bokemeyer
Journal:  Cancer Manag Res       Date:  2009-07-23       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.